Cat. No. 2420
Alternative Name: [pGlu1]-Apelin-13
Biological ActivityHighly potent pyroglutamyl form of apelin-13. Endogenous ligand for apelin APJ receptor (EC50 = 0.37 nM) that displays potent vascular effects in vivo.
(Modifications: X = pGlu)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Tatemoto et al (1998) Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem.Biophys.Res.Comm. 251 471.
Katugampola et al (2001) [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br.J.Pharmacol. 132 1255. PMID: 11250876.
Kagiyama et al (2005) Central and peripheral cardiovascular actions of apelin in conscious rats. Regul.Pept. 125 55. PMID: 15582714.
Kleinz et al (2005) Emerging roles of apelin in biology and medicine. Pharmacol.Ther. 107 198. PMID: 15907343.
If you know of a relevant citation for this product please let us know.
Keywords: [Pyr1]-Apelin-13, supplier, Potent, peptide, agonists, APJ, Receptors, Apelin, adipokines
Find multiple products by catalog number
New Products in this Area
Synthetic version of amylin (Cat. No. 3418)SB 706375
High affinity, non-peptide UT receptor antagonistPG 106
Selective MC3 receptor antagonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.